Overview

First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects

Status:
Recruiting
Trial end date:
2022-10-05
Target enrollment:
Participant gender:
Summary
To evaluate the safety of 2 dose vaccination schedule of orally administered CoV2-OGEN1 In healthy subjects
Phase:
Phase 1
Details
Lead Sponsor:
Syneos Health
Collaborator:
US Specialty Formulations, LLC